Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neoplasma (Bratislava)

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4149/neo_2014_071PMID 25030442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Touch-Down Reverse Transcriptase-PCR Detection of IgVH Rearrangement and Sybr-Green-Based Real-Time RT-PCR Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia

  2012cited by this paper
• From pathogenesis to treatment of chronic lymphocytic leukaemia

  2010cited by this paper
• Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features

  2010cited by this paper
• Regulation of FGF‐2 by an endogenous antisense RNA: Effects on cell adhesion and cell‐cycle progression

  2010cited by this paper
• Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

  2009cited by this paper
• Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis.

  2008cited by this paper
• Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy

  2008cited by this paper
• Dysregulated angiogenesis in B-chronic lymphocytic leukemia: Morphologic, immunohistochemical, and flow cytometric evidence

  2008cited by this paper
• Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2‐dependent TGF‐β signaling

  2007cited by this paper
• Novel biochemical pathways of endoglin in vascular cell physiology

  2007cited by this paper
• [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].

  2007cited by this paper
• Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status

  2007cited by this paper
• Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia.

  2007cited by this paper
• Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status

  2006cited by this paper
• Angiopoietin-2 Expression in B-Cell Chronic Lymphocytic Leukemia: Association with Clinical Outcome and Immunoglobulin Heavy-Chain Mutational Status.

  2006cited by this paper
• Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia.

  2006cited by this paper
• Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.

  2005cited by this paper
• Expression of Angiopoietin-2 in Endothelial Cells Is Controlled by Positive and Negative Regulatory Promoter Elements

  2004cited by this paper
• Endoglin Controls Cell Migration and Composition of Focal Adhesions

  2004cited by this paper
• Differential levels of soluble endoglin (CD105) in myeloid malignancies

  2003cited by this paper
• FGF-2 expression and its action in human leukemia and lymphoma cell lines

  2003cited by this paper
• ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

  2003cited by this paper
• CD105 prevents apoptosis in hypoxic endothelial cells

  2003cited by this paper
• Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia

  2002cited by this paper
• Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia.

  2002cited by this paper
• Role of angiogenesis in tumor growth and metastasis.

  2002cited by this paper
• Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia.

  2002cited by this paper
• B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

  2002cited by this paper
• Bcl‐2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia

  2001cited by this paper
• Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.

  2000cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000cited by this paper
• In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells.

  2000cited by this paper
• Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

  2000cited by this paper
• Evidence of increased angiogenesis in patients with acute myeloid leukemia.

  2000cited by this paper
• Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

  1999cited by this paper
• Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

  1997cited by this paper
• Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis

  1997cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper
• Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine.

  1996cited by this paper
• Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction

  1995cited by this paper
• Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia.

  1995cited by this paper

• Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?

  2024cites this paper
• An overview of the molecular and clinical significance of the angiopoietin system in leukemia

  2023cites this paper
• A comprehensive insight into the role of molecular pathways affected by the Angiopoietin and Tie system involved in hematological malignancies' pathogenesis.

  2023cites this paper
• Identification of CD105 (endoglin) as novel risk marker in CLL

  2022influential citation
• Tie-2 Expressing Monocytes in The Pathogenesis of Chronic Lymphocytic Leukemia

  2021cites this paper
• Unfavourable biological prognostic factors in Multiple Myeloma

  2019cites this paper
• Microarray Classification and Gene Selection with FS-NEAT

  2018cites this paper